Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge?
Matteo Megna, Sonia Sofìa Ocampo‐Garza, Luca Potestio, et al.
Biomedicines (2021) Vol. 9, Iss. 10, pp. 1482-1482
Open Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

New frontiers in personalized medicine in psoriasis
Elisa Camela, Luca Potestio, Gabriella Fabbrocini, et al.
Expert Opinion on Biological Therapy (2022) Vol. 22, Iss. 12, pp. 1431-1433
Closed Access | Times Cited: 55
Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study
Matteo Megna, Luca Potestio, Angelo Ruggiero, et al.
Journal of Dermatological Treatment (2022) Vol. 33, Iss. 5, pp. 2560-2564
Closed Access | Times Cited: 51
Risankizumab treatment in psoriasis patients who failed anti‐IL17: A 52‐week real‐life study
Matteo Megna, Luca Potestio, Angelo Ruggiero, et al.
Dermatologic Therapy (2022) Vol. 35, Iss. 7
Open Access | Times Cited: 50
Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single‐center retrospective study in a real‐life setting
Matteo Megna, Luca Potestio, Elisa Camela, et al.
Dermatologic Therapy (2022) Vol. 35, Iss. 9
Open Access | Times Cited: 43
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients
Matteo Megna, Elisa Camela, Teresa Battista, et al.
Expert Opinion on Drug Safety (2023) Vol. 22, Iss. 1, pp. 25-41
Closed Access | Times Cited: 42
Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study
Matteo Megna, Angelo Ruggiero, Teresa Battista, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 9, pp. 3233-3233
Open Access | Times Cited: 30
Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation
Angelo Ruggiero, Luca Potestio, Fabrizio Martora, et al.
Expert Opinion on Drug Safety (2023) Vol. 22, Iss. 5, pp. 355-362
Closed Access | Times Cited: 30
The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials
Luca Potestio, Fabrizio Martora, Giuseppe Lauletta, et al.
Clinical Cosmetic and Investigational Dermatology (2024) Vol. Volume 17, pp. 829-842
Open Access | Times Cited: 10
Pathophysiology and Treatment of Psoriasis: From Clinical Practice to Basic Research
Yujie Gao, Tianqi Xu, Yu Wang, et al.
Pharmaceutics (2025) Vol. 17, Iss. 1, pp. 56-56
Open Access | Times Cited: 1
The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review
Angelo Ruggiero, Fabrizio Martora, Gabriella Fabbrocini, et al.
Clinical Cosmetic and Investigational Dermatology (2022) Vol. Volume 15, pp. 2785-2793
Open Access | Times Cited: 36
Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge
Angelo Ruggiero, Luca Potestio, Elisa Camela, et al.
Psoriasis Targets and Therapy (2022) Vol. Volume 12, pp. 127-137
Open Access | Times Cited: 35
Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?
Matteo Megna, Elisa Camela, Angelo Ruggiero, et al.
Clinical Cosmetic and Investigational Dermatology (2023) Vol. Volume 16, pp. 1677-1690
Open Access | Times Cited: 21
Management of Psoriasis Patients with Serious Infectious Diseases
Matteo Megna, Giuseppe Lauletta, Nello Tommasino, et al.
Advances in Therapy (2024) Vol. 41, Iss. 6, pp. 2099-2111
Open Access | Times Cited: 8
Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge
Angelo Ruggiero, Elisa Camela, Luca Potestio, et al.
Expert Opinion on Drug Safety (2022) Vol. 21, Iss. 12, pp. 1445-1451
Closed Access | Times Cited: 26
JAK Inhibitors in Psoriatic Disease
Matteo Megna, Luca Potestio, Angelo Ruggiero, et al.
Clinical Cosmetic and Investigational Dermatology (2023) Vol. Volume 16, pp. 3129-3145
Open Access | Times Cited: 16
Biologics for the Management of Erythrodermic Psoriasis: An Updated Review
Luca Potestio, Elisa Camela, Sara Cacciapuoti, et al.
Clinical Cosmetic and Investigational Dermatology (2023) Vol. Volume 16, pp. 2045-2059
Open Access | Times Cited: 14
Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study
Matteo Megna, Luca Potestio, Gabriella Fabbrocini, et al.
Psoriasis Targets and Therapy (2022) Vol. Volume 12, pp. 205-212
Open Access | Times Cited: 22
Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas
Sara Cacciapuoti, Luca Potestio, Gianluca Guerrasio, et al.
Clinical Cosmetic and Investigational Dermatology (2023) Vol. Volume 16, pp. 2637-2644
Open Access | Times Cited: 8
New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge
Luca Potestio, Teresa Battista, Sara Cacciapuoti, et al.
Biomedicines (2023) Vol. 11, Iss. 8, pp. 2191-2191
Open Access | Times Cited: 7
Paradoxical reactions to biologicals for psoriasis
Elisa Camela, Luca Potestio, Gabriella Fabbrocini, et al.
Expert Opinion on Biological Therapy (2022) Vol. 22, Iss. 12, pp. 1435-1437
Closed Access | Times Cited: 12
Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation
Luca Potestio, Nello Tommasino, Giuseppe Lauletta, et al.
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 6, pp. 677-685
Closed Access | Times Cited: 2
The Impact of COVID-19 Vaccination on Inflammatory Skin Disorders and Other Cutaneous Diseases: A Review of the Published Literature
Fabrizio Martora, Teresa Battista, Angelo Ruggiero, et al.
Viruses (2023) Vol. 15, Iss. 7, pp. 1423-1423
Open Access | Times Cited: 6
Efficacy and safety of spesolimab for the management of generalized pustular psoriasis: a drug safety evaluation
Luca Potestio, Elisa Camela, Sara Cacciapuoti, et al.
Expert Opinion on Drug Safety (2023) Vol. 22, Iss. 11, pp. 1003-1010
Closed Access | Times Cited: 4
The Challenge Arising from New Knowledge about Immune and Inflammatory Skin Diseases: Where We Are Today and Where We Are Going
Anna Campanati, Emanuela Martina, Annamaria Offidani
Biomedicines (2022) Vol. 10, Iss. 5, pp. 950-950
Open Access | Times Cited: 6
Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis
Luca Potestio, Fabrizio Martora, Gabriella Fabbrocini, et al.
Psoriasis Targets and Therapy (2023) Vol. Volume 13, pp. 11-18
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top